US2022143015A1PendingUtilityA1
Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
Assignee: AFFERENT PHARMACEUTICALS INCPriority: Sep 29, 2015Filed: Jan 24, 2022Published: May 12, 2022
Est. expirySep 29, 2035(~9.2 yrs left)· nominal 20-yr term from priority
A61K 9/0078A61K 9/0053A61K 9/06A61K 45/06A61K 9/0014A61K 31/505A61K 47/38A61K 9/10A61K 47/44A61K 9/2054A61P 11/14A61K 9/4858A61P 43/00A61P 11/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
Claims
exact text as granted — not AI-modified1 . A method for treating chronic cough, comprising administering to a patient with chronic cough about 15 mg twice daily of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or C 1 -C 6 alkyl; and
R 2 is: alkyl; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; carboxyalkyl; cyano or alkylcarbonyl; and
wherein the method exhibits a reduced taste disturbance relative to a taste disturbance resulting from administering a dose of about 100 mg or greater of the compound of formula (I) or the pharmaceutically acceptable salt thereof twice daily to a patient with chronic cough.
2 . The method of claim 1 , wherein the chronic cough is idiopathic or treatment resistant cough.
3 - 4 . (canceled)
5 . The method of claim 1 , wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered twice daily for days, weeks, months or years.
6 . The method of claim 1 , wherein the chronic cough is refractory chronic cough.
7 . The method of claim 1 , wherein the reduced taste disturbance is relative to a taste disturbance resulting from administering about 100 mg of the compound of Formula (I) or the pharmaceutically acceptable salt thereof twice daily to a patient with chronic cough.
8 . The method of claim 1 , wherein the chronic cough is daytime cough.
9 - 10 . (canceled)
11 . The method of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
12 . The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13 - 20 . (canceled)
21 . A method for treating chronic cough, comprising administering to a patient with chronic cough about 15 mg twice daily of a pharmaceutically acceptable salt of the following compound:
wherein the method exhibits a reduced taste disturbance relative to a taste disturbance resulting from administering a dose of about 100 mg or greater of the pharmaceutically acceptable salt of the compound of formula (I) twice daily to a patient with chronic cough.
22 . The method of claim 21 , wherein the reduced taste disturbance is relative to a taste disturbance resulting from administering about 100 mg of the pharmaceutically acceptable salt of the compound of formula (I) twice daily to a patient with chronic cough.
23 - 26 . (canceled)
27 . The method of claim 21 , wherein the reduced taste disturbance is relative to a taste disturbance resulting from administering about 600 mg of the pharmaceutically acceptable salt of the compound of formula (I) twice daily to a patient with chronic cough.Join the waitlist — get patent alerts
Track US2022143015A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.